EQUITY RESEARCH – RESULTS FLASH



4Q23 results at first glance

PR9 posted a new record revenue, EBITDA margin and core profit of THB188m in 4Q23, beating our estimate

Highlights

- PR9 reported a new record core profit of THB188m for 4Q23 (+36% y-y, +34% q-q), beating Bloomberg's consensus and our estimate by 10% due to a higher-than-expected EBITDA margin.
- Revenue grew 6% y-y in 4Q23. Thai patient revenue grew by 6% y-y, while international patient revenue grew by 9% y-y, led by higher patient revenue from Myanmar, China and Cambodia.
- Thai patient and international patient revenues hit record highs, and revenues exceeded the pre-Covid levels by 57% and 50%, respectively.
- The revenue contribution from Thai patients made up an 86% proportion in the quarter, while international patient revenue made up 14%.
- SG&A declined by 4% y-y due to the high base in 4Q22 following the additional bonus expenses to employees. COGS increased by 4% yy following the revenue increase. As a result, the EBITDA margin jumped to 26% in 4Q23 (vs 22% in 4Q22); a record high (excluding the Covid pandemic period).
- PR9 announced a dividend of THB0.3/shr, implying a dividend yield of 2%.

Outlook and recommendation

- We expect the momentum to continue in 1Q24. IPD volume remained strong in Jan and Feb. In addition, PR9 has started serving Middle East patients. Thus, we expect strong earnings growth y-y in 1Q24.
- PR9 is trading at a cheap valuation of 23x 2024E P/E (vs its peers' avg. of 26x). PR9 is one of our top picks for mid-small caps due to its promising outlook.

TARGET PRICE	THB22.00
CLOSE	THB17.80
UP/DOWNSIDE	+23.6%
PRIOR TP	THB22.00
CHANGE IN TP	UNCHANGED
TP vs CONSENSUS	+10.7%

KEY STOCK DATA

PR9 TB

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	4,202	4,549	4,826	5,120
Net profit	558	603	656	721
EPS (THB)	0.71	0.77	0.83	0.92
vs Consensus (%)	-	15.6	11.6	11.5
EBITDA	958	1,057	1,138	1,237
Recurring net profit	558	603	656	721
Core EPS (THB)	0.71	0.77	0.83	0.92
Chg. In EPS est. (%)	nm	0.0	0.0	nm
EPS growth (%)	(1.7)	8.2	8.7	9.9
Core P/E (x)	25.1	23.2	21.3	19.4
Dividend yield (%)	1.7	2.2	2.3	2.6
EV/EBITDA (x)	12.6	11.1	9.9	8.8
Price/book (x)	2.8	2.6	2.4	2.3
Net debt/Equity (%)	(37.3)	(42.3)	(46.5)	(50.5)
ROE (%)	11.4	11.5	11.7	12.0



Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFA Fundamental Investment Analyst on Securities; License no. 080523 teerapol.udo@fssia.com, +66 2646 9969

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

Exhibit 1: PR9 - 4Q23 results summary

FY ending Dec	4Q22	1Q23	2Q23	3Q23	4Q23	Cha	nge	2023	2024E	Change
	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(у-у %				
Sales	1,103	957	1,005	1,066	1,175	10	6	4,202	4,549	
COGS (incl depreciation)	(730)	(657)	(688)	(714)	(761)	6	4	(2,820)	(3,048)	
Gross profit	373	300	316	351	414	18	11	1,382	1,501	
SG&A	(218)	(182)	(185)	(198)	(209)	6	(4)	(774)	(818)	
Operating profit	155	118	132	154	205	33	32	608	683	1
Net other income	17	16	17	19	28	45	67	81	71	(1)
Interest expenses	(0)	(0)	(0)	(0)	(0)			(1)	0	n
Pretax profit	172	134	149	173	233	35	36	689	754	1
Income Tax	(33)	(25)	(28)	(33)	(45)	36	35	(131)	(151)	-
Core profit	139	109	121	140	188	34	36	558	603	
Extraordinaries, GW & FX										
Reported net profit	139	109	121	140	188	34	36	558	603	
Outstanding shares (m)	786	786	786	786	786	0	0	786	786	
Pre-ex EPS (THB)	0.18	0.14	0.15	0.18	0.24	34	36	0.71	0.77	
EPS (THB)	0.18	0.14	0.15	0.18	0.24	34	36	0.71	0.77	
COGS excl. depreciation	(656)	(584)	(614)	(638)	(686)	7	4	(2,521)	(2,725)	
Depreciation	(74)	(73)	(75)	(76)	(75)	(1)	1	(299)	(323)	
EBITDA	246	207	224	249	308	24	25	988	1,077	
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(PI
Gross margin	34	31	31	33	35	2	1	33	33	
SG&A/Revenue	20	19	18	19	18	(1)	(2)	18	18	(
EBITDA margin	22	21	22	23	26	3	4	23	23	
Net profit margin	13	11	12	13	16	3	3	13	13	(
Operating stats	(%)	(%)	(%)	(%)	(%)					
OPD revenue growth y-y	20	6	5	4	3					
OPD volume growth y-y	13	8	4	5	-					
OPD revenue per head growth y-y	6	(2)	1	(0)	-					
IPD revenue growth y-y	15	(11)	1	(5)	12					
IPD volume growth y-y	5	(35)	(10)	(11)	-					
IPD revenue per head growth y-y	10	38	13	6	-					
Thai patient revenue growth y-y	11	(5)	4	1	6					
Inter patient revenue growth y-y	96	29	1	(5)	9					

Sources: PR9; FSSIA estimates

Exhibit 2: EBITDA margin





Exhibit 3: Core profit



Sources: PR9; FSSIA estimates

Sources: PR9; FSSIA estimates

Financial Statements

Praram 9 Hospital

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	4,107	4,202	4,549	4,826	5,120
Cost of goods sold	(2,724)	(2,820)	(3,048)	(3,224)	(3,406)
Gross profit	1,384	1,382	1,501	1,602	1,714
Other operating income	43	51	51	52	53
Operating costs	(735)	(774)	(818)	(859)	(896)
Operating EBITDA	991	958	1,057	1,138	1,237
Depreciation	(299)	(299)	(323)	(343)	(365)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	692	659	734	795	872
Net financing costs	8	30	20	25	29
Associates	0	0	0	0	0
Recurring non-operating income	0	0	0	0	0
Non-recurring items	0	0	0	0	0
Profit before tax	700	689	754	820	901
Tax	(132)	(131)	(151)	(164)	(180)
Profit after tax	568	558	603	656	721
Minority interests	0	0	0	0	0
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	568	558	603	656	721
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	568	558	603	656	721
Per share (THB)					
Recurring EPS *	0.72	0.71	0.77	0.83	0.92
Reported EPS	0.72	0.71	0.77	0.83	0.92
DPS	0.29	0.30	0.38	0.42	0.46
Diluted shares (used to calculate per share data)	786	786	786	786	786
Growth					
Revenue (%)	37.5	2.3	8.3	6.1	6.1
Operating EBITDA (%)	67.9	(3.4)	10.3	7.7	8.6
Operating EBIT (%)	133.3	(4.7)	11.4	8.3	9.7
Recurring EPS (%)	127.8	(1.7)	8.2	8.7	9.9
Reported EPS (%)	127.8	(1.7)	8.2	8.7	9.9
Operating performance		(,			
Gross margin inc. depreciation (%)	33.7	32.9	33.0	33.2	33.5
Gross margin exc. depreciation (%)	41.0	40.0	40.1	40.3	40.6
Operating EBITDA margin (%)	24.1	22.8	23.2	23.6	24.2
Operating EBIT margin (%)	16.8	15.7	16.1	16.5	17.0
Net margin (%)	13.8	13.3	13.3	13.6	14.1
Effective tax rate (%)	18.9	19.0	20.0	20.0	20.0
Dividend payout on recurring profit (%)	40.2	42.3	50.0	50.0	50.0
Interest cover (X)	(84.0)	(22.3)	(36.8)	(32.1)	(30.1)
Inventory days	8.1	7.2	6.7	6.8	(30.1) 6.8
Debtor days	20.2	23.1	23.3	21.9	20.7
Creditor days	82.5	73.9	72.7	73.5	73.5
Operating ROIC (%)	62.5 18.1	17.6	19.3	21.2	23.5
ROIC (%)	17.4	16.1	19.5	19.2	23.5
ROE (%)	17.4	11.4	11.5	19.2	12.0
ROE (%) ROA (%)	12.6	9.3	9.6		
* Pre-exceptional, pre-goodwill and fully diluted	10.3	9.0	9.0	9.7	10.1
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
OPD patient revenue	2,383	2,491	2,621	2,781	2,950
IPD patient revenue	1,725	1,711	1,928	2,045	2,169

Sources: Praram 9 Hospital; FSSIA estimates

Financial Statements

Praram 9 Hospital

Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	568	558	603	656	72
Depreciation	299	299	323	343	365
ssociates & minorities	-	-	-	-	
ther non-cash items	10	10	0	0	(
hange in working capital	(5)	(23)	46	35	37
ash flow from operations	871	844	972	1,034	1,122
Capex - maintenance	(140)	(326)	(323)	(343)	(364
Capex - new investment	-	-	-	-	
let acquisitions & disposals	(150)	(100)	0	0	(
Other investments (net)	-	-	-	-	
Cash flow from investing	(290)	(426)	(323)	(343)	(364
Dividends paid	(110)	(234)	(236)	(302)	(328
quity finance	0	0	0	0	(
Debt finance	2 0	1 0	0 0	0 0	(
Other financing cash flows					-
cash flow from financing	(108)	(233)	(236)	(302)	(328
lon-recurring cash flows	-	- 0	-0	- 0	(
Other adjustments	0	0	0	0	(
let other adjustments lovement in cash	473	184	413	390	430
ree cash flow to firm (FCFF)	581.44	418.17	648.69	691.26	757.76
ree cash flow to equity (FCFE)	582.47	418.73	648.69	691.26	757.76
	502.47	+10.75	0-0.03	001.20	151.10
er share (THB)	:				
CFF per share	0.74	0.53	0.82	0.88	0.96
CFE per share	0.74 1.11	0.53 1.10	0.82 1.18	0.88 1.27	0.9 1.3
ecurring cash flow per share	1.11	1.10	1.10	1.27	1.30
alance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
angible fixed assets (gross)	5,638	5,898	6,222	6,565	6,929
ess: Accumulated depreciation	(2,322)	(2,556)	(2,878)	(3,222)	(3,586
angible fixed assets (net)	3,315	3,343	3,343	3,343	3,343
ntangible fixed assets (net)	0	0	0	0	0,01
ong-term financial assets	-	-	-	-	
nvest. in associates & subsidiaries	154	254	254	254	254
Cash & equivalents	1,717	1,901	2,314	2,704	3,134
/C receivable	243	290	290	290	290
iventories	51	48	52	55	58
Other current assets	12	12	13	14	14
Current assets	2,023	2,251	2,669	3,063	3,496
Other assets	65	62	62	62	62
otal assets	5,558	5,910	6,328	6,722	7,155
Common equity	4,735	5,080	5,447	5,801	6,194
/inorities etc.	0	0	0	0	(
otal shareholders' equity	4,735	5,080	5,447	5,801	6,194
ong term debt	8	9	9	9	ç
ther long-term liabilities	209	195	195	195	195
ong-term liabilities	217	204	204	204	204
/C payable	499	522	564	596	629
hort term debt	0	0	0	0	(
Other current liabilities	106	105	113	120	127
urrent liabilities	606	626	677	716	757
otal liabilities and shareholders' equity	5,558	5,910	6,328	6,722	7,155
let working capital	(299)	(276)	(322)	(357)	(394
wested capital Includes convertibles and preferred stock which is beir	3,235 a treated as debt	3,382	3,337	3,302	3,264
· ·					
er share (THB)					
ook value per share	6.02	6.46	6.93	7.38	7.88
angible book value per share	6.02	6.46	6.93	7.38	7.88
inancial strength					
let debt/equity (%)	(36.1)	(37.3)	(42.3)	(46.5)	(50.5
let debt/total assets (%)	(30.8)	(32.0)	(36.4)	(40.1)	(43.7
current ratio (x)	3.3	3.6	3.9	4.3	4.6
F interest cover (x)	(69.7)	(13.2)	(31.5)	(26.9)	(25.2
aluation	2022	2023	2024E	2025E	2026
ecurring P/E (x) *	24.7	25.1	23.2	21.3	19.4
ecurring P/E @ target price (x) *	30.5	31.0	28.7	26.4	24.0
eported P/E (x)	24.7	25.1	23.2	21.3	24. 19.4
ividend yield (%)	1.6	1.7	2.2	21.3	2.
rice/book (x)	3.0	2.8	2.6	2.4	2.3
rice/tangible book (x)	3.0	2.8	2.6	2.4	2.3
V/EBITDA (x) **	12.4	12.6	11.1	9.9	8.8
	15.7	16.1	14.2	12.8	11.5
V/EBIIDA (a) target price (x) **					
EV/EBITDA @ target price (x) ** EV/invested capital (x)	3.8	3.6	3.5	3.4	3.3

Sources: Praram 9 Hospital; FSSIA estimates



Praram 9 Hospital PCL (PR9 TB)



54.08 /100

Exhibit 4: FSSIA ESG score implication

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
$\star\star\star\star$	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 5: ESG – peer comparison

	FSSIA			Dome	estic ratings			Global ratings						Bloomberg		
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score	
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17	
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94	
BCH	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60	
BDMS	74.00	Y	Y	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92	
BH	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79	
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24	
PR9	54.08		Y	Y	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90	
PRINC	18.00				4.00	4.00	Certified									
RAM	11.75				3.00			High								
THG	18.75				5.00	5.00		High								
VIBHA	20.88				4.00	3.00	Declared	High					17.00			

Sources: <u>SETTRADE.com</u>; FSSIA's compilation

Exhibit 6: ESG score by Bloomberg

FY ending Dec 31	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	_	2.33	2.43
BESG environmental pillar score	_	2.56	2.18
BESG social pillar score	_	1.36	1.52
BESG governance pillar score	_	4.13	4.46
ESG disclosure score	-	37.90	37.90
Environmental disclosure score	_	11.78	11.78
Social disclosure score	—	20.68	20.68
Governance disclosure score	—	81.10	81.10
Environmental			
Emissions reduction initiatives	No	Yes	Yes
Climate change policy	No	Yes	Yes
Climate change opportunities discussed	No	No	No
Risks of climate change discussed	No	No	No
GHG scope 1	—	0	0
GHG scope 2 location-based	—	4	6
GHG Scope 3	—	0	5
Carbon per unit of production	—	—	—
Biodiversity policy	No	No	No
Energy efficiency policy	No	Yes	Yes
Total energy consumption	—	7	13
Renewable energy use	—	—	—
Electricity used	—	—	—
Fuel used - natural gas	—	_	_

Sources: Bloomberg; FSSIA's compilation

Exhibit 7: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No
Waste reduction policy	No	Yes	Yes
Hazardous waste	—	—	—
Total waste	—	—	_
Waste recycled	—	—	-
Waste sent to landfills	—	—	_
Environmental supply chain management	No	No	No
Water policy	No	Yes	Yes
Water consumption		60	151
Social			
Human rights policy	Yes	Yes	Yes
Policy against child labor	No	Yes	Yes
Quality assurance and recall policy	No	Yes	Yes
Consumer data protection policy	No	Yes	Yes
Equal opportunity policy	Yes	Yes	Yes
Gender pay gap breakout	No	No	No
Pct women in workforce	—	_	_
Pct disabled in workforce	—	_	_
Business ethics policy	No	Yes	Yes
Anti-bribery ethics policy	Yes	Yes	Yes
Health and safety policy	No	Yes	Yes
Lost time incident rate - employees	—	—	_
Total recordable incident rate - employees	—	1	0
Training policy	Yes	Yes	Yes
Fair remuneration policy	No	No	No
Number of employees – CSR	2,083	1,987	2,011
Employee turnover pct	—	11	13
Total hours spent by firm - employee training	14,566	13,462	66,852
Social supply chain management	No	No	No
Governance			
Board size	10	10	9
No. of independent directors (ID)	4	7	6
No. of women on board	2	2	2
No. of non-executive directors on board	7	7	6
Company conducts board evaluations	Yes	Yes	Yes
No. of board meetings for the year	7	7	7
Board meeting attendance pct	97	100	89
Board duration (years)	3	3	3
Director share ownership guidelines	No	No	No
Age of the youngest director	56	56	57
Age of the oldest director	72	73	74
No. of executives / company managers	7	5	5
No. of female executives	2	0	0
Executive share ownership guidelines	No	No	No
Size of audit committee	3	3	3
No. of ID on audit committee	3	3	3
Audit committee meetings	4	4	4
Audit meeting attendance %	100	100	100
Size of compensation committee	3	3	3
No. of ID on compensation committee	3	2	3
No. of compensation committee meetings	2	2	2
Compensation meeting attendance %	83	100	100
Size of nomination committee	3	3	3
No. of nomination committee meetings	2	2	2
Nomination meeting attendance %	83	100	100
Sustainability governance			
Verification type	No	No	No

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodolog	У			Rating						
The Dow Jones Sustainability Indices (<u>DJSI</u>) By S&P Global	process base from the ann Only the top- inclusion.	ed on the con ual S&P Glob ranked comp	transparent, rules-based npanies' Total Sustainabi pal Corporate Sustainabil panies within each industr	lity Scores resulting ity Assessment (CSA). ry are selected for	Sustainability As ESG Score of le scoring compan selected from th	ssessment (C ss than 45% y are disquali e Eligible Uni		mpanies with al ESG Score lents of the D	an S&P Globa of the highest JSI indices are		
Sustainability Investment List (<u>THSI</u>) by The Stock Exchange of Thailand (<u>SET</u>)	managing bu Candidates r 1) no irregula float of >150 up capital. S 70%; 2) inde wrongdoing	usiness with tranust pass the ar trading of the shareholders ome key disq pendent direct related to CG	sility in Environmental and ransparency in Governan a preemptive criteria, with the board members and e s, and combined holding jualifying criteria include: ctors and free float violati a, social & environmental earnings in red for > 3 year	ace, updated annually. two crucial conditions: executives; and 2) free must be >15% of paid- 1) CG score of below on; 3) executives' impacts; 4) equity in	To be eligible for <u>THSI inclusion</u> , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJS during the assessment year. The scoring will be fairly weighted against t nature of the relevant industry and materiality. <u>SETTHSI Index</u> is extended from the THSI companies whose 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight maximum, and no cap for number of stocks.						
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by t Thailand (SE	he Thai IOD,	th in sustainable develop with support from the St Its are from the perspecti Is.	ock Exchange of	Good (80-89), 3 and not rated for equitable treatm	for Good (70 r scores belov ent of shareh 5%); 4) disclos	ories: 5 for Excell -79), 2 for Fair (6 v 50. Weightings olders (weight 25 sure & transpare	0-69), 1 for F include: 1) th % combined	Pass (60-69), ne rights; 2) and); 3) the role of		
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment are transparent a out of five the criteria cover date (45%), a circulation of s exercised. The and verifiability	e incorporated and sufficientl e CG compor r AGM proced and after the ufficient informat second assess r; and 3) opennet	which shareholders' right d into business operation ly disclosed. All form imp- nents to be evaluated anr dures before the meeting meeting (10%). (The first a stion for voting; and 2) facilita ses 1) the ease of attending n ess for Q&A. The third involve ues, resolutions and voting re	s and information is ortant elements of two nually. The assessment (45%), at the meeting ssesses 1) advance ting how voting rights can be neetings; 2) transparency as the meeting minutes that	nd information is Very Good (90-99), 3 for Fair (80-89), and not rated for scores below nt elements of two ly. The assessment %), at the meeting sses 1) advance how voting rights can be ings; 2) transparency e meeting minutes that						
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishmer policies. The (Companies de Declaration of Certification, in managers and	The core elements of the Checklist include corruption risk assessment, establishment of key controls, and the monitoring and developing of policies. The Certification is good for three years. (Companies deciding to become a CAC certified member start by submitting a Declaration of Intent to kick off an 18-month deadline to submit the CAC Checklist for Certification, including risk assessment, in place of policy and control, training of managers and employees, establishment of whistleblowing channels, and communication of policies to all stakeholders.)						CAC Council			
<u>Morningstar</u> Sustainalytics	based on an risk is unmar regulatory filing	The Sustainalytics' ESG risk rating provides an overall company score ased on an assessment of how much of a company's exposure to ESG sk is unmanaged. Sources to be reviewed include corporate publications and gulatory filings, news and other media, NGO reports/websites, multi-sector formation company feedback. ESG controversies issuer freedback on draft ESG to the sector of th						ed risk. The Severe			
		impany feedbad Jality & peer rev	ck, ESG controversies, issuer views.	Teedback on draft ESG	0-10	10-20	20-30	30-40	40+		
ESG Book	positioned to the principle helps explair over-weightin	outperform o of financial m future risk-a	sustainable companies the sover the long term. The me nateriality including inform djusted performance. Ma ith higher materiality and erly basis.	nethodology considers nation that significantly ateriality is applied by	scores using ma	teriality-base	ated as a weighte d weights. The so dicating better pe	core is scaled			
<u>MSCI</u>				anagement of financially their exposure to ESG rise					nethodology to		
	AAA	8.571-10.00	00 Leader:	leading its industry in m	anaging the most sig	nificant ESG ris	ks and opportunitie	e			
	AA	7.143-8.57	0	loading to madely in m	anaging the most sig						
	A	5.714-7.14		a mixed or unexception	al track record of ma	naging the most	significant ESG ris	ks and opportu	nities relative to		
	BBB BB	4.286-5.71 2.857-4.28	-	industry peers							
	В	1.429-2.85	6								
	ccc	0.000-1.42	Laggard:	lagging its industry base	ed on its high exposu	re and failure to	manage significant	ESG risks			
Moody's ESG solutions	believes that	esses the deg a company i	gree to which companies	take into account ESG o to its business model and medium to long term.	,		1				
<u>Refinitiv ESG</u> rating	based on pu	blicly availabl	e and auditable data. The	e a company's relative ES e score ranges from 0 to are 0 to 25 = poor; >25 to 50	100 on relative ES	G performan	ce and insufficier	nt degree of t			
S&P Global				asuring a company's perf ssification. The score ran			of ESG risks, opp	oortunities, ar	nd impacts		
Bloomberg	ESG Score	compared to its peers within the same industry classification. The score ranges from 0 to 100. ESG Score Bloomberg score evaluating the company's aggregated Environmental, Social and Governance (ESG) performance. The score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean) of Pillar Scores, where the weights are determined by the pillar priority ranking. Values range from 0 to 10; 10 is the best.									
			of Pillar Scores, where	the weights are determin	ed by the pillar pr	iority ranking.	Values range fro	om 0 to 10; 10) is the best.		

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings. Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Praram 9 Hospital	PR9 TB	THB 17.80	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected expenses from its new building.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 19-Feb-2024 unless otherwise stated.



RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months. **Neutral.** The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months. **Underweight.** The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

